[Characteristics of neoplasm occurrence of renal allograft recipients and their prognosis].
OBJECTIVE
Renal allograft recipients are more likely to develop neoplasm than general population because of long-term immunosuppressive treatment and concurrent infections. This study was designed to analyze the clinical features of neoplasm occurrence of renal allograft recipients, and the effect of radical surgery (RS) on their prognosis.


METHODS
Records of 2 160 renal allograft recipients treated in our center from Oct. 1987 to Apr. 2003 were retrospectively studied. The time to neoplasm development, pathologic type of tumor, patients' survival time were analyzed to explore the clinical features of neoplasm developing after kidney transplantation. Recipients developed neoplasms were divided into RS group and non-RS group according to their treatment pattern. The effect of RS on patients' survival was estimated.


RESULTS
A total of 33 patients developed neoplasms after transplantation. Among them,11(33.3%) developed neoplasms in digestive system. The median survival time of RS group (10 patients) was 41.5 months, that of non-RS group (23 patients) was 6.0 months. The 20-month survival rate of RS group was 70.0%, while that of non-RS group was 13.0%.


CONCLUSIONS
Renal allograft recipients are more likely to develop neoplasm than general population. Moreover, their main malignancies are liver cancer, skin cancer, lymphoma and thyroid carcinoma, which differ from those observed in general population. Early diagnosis and treatment, especially feasible RS, will improve short-term outcome, while long-term therapeutic effect needs to be further observed.
Wang
Chang-Xi
CX
Department of Organ Transplantation, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510080, P. R. China. wcx16321@163.com
Liu
Long-Shan
LS
Chen
Li-Zhong
LZ
Wu
Pei-Gen
PG
Xie
Dan
D
Fei
Ji-Guang
JG
Qiu
Jiang
J
Deng
Su-Xiong
SX
Zheng
Ke-Li
KL
Ji
Yu-Lian
YL
Zhu
Lan-Ying
LY
Shen
Qing-Rui
QR
He
Xiao-Shun
XS
D000328:Adult; D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000009:adverse effects*; D008113:Liver Neoplasms / Q000209:etiology* / Q000401:mortality; D008223:Lymphoma / Q000209:etiology / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000209:etiology / Q000401:mortality; D015996:Survival Rate; D013964:Thyroid Neoplasms / Q000209:etiology / Q000401:mortality
D007166:Immunosuppressive Agents